HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.
Company profile
Ticker
HLVX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Exelixis ...
SEC CIK
Corporate docs
Subsidiaries
HilleVax Securities Corporation ...
HLVX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
22 May 23
S-3
Shelf registration
12 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
12 May 23
DEFA14A
Additional proxy soliciting materials
10 May 23
8-K
Departure of Directors or Certain Officers
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Other Events
25 Apr 23
Latest ownership filings
4
Nanette Cocero
10 May 23
3
Nanette Cocero
10 May 23
SC 13D/A
Frazier Life Sciences Public Fund, L.P.
5 May 23
SC 13G
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
SC 13G/A
Carlyle Group Inc.
10 Feb 23
SC 13G/A
Flynn James E
10 Feb 23
4
Astrid Borkowski
3 Feb 23
4
Aditya Kohli
3 Feb 23
4
ROBERT HERSHBERG
3 Feb 23
4
Shane Maltbie
3 Feb 23
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 262.17 mm | 262.17 mm | 262.17 mm | 262.17 mm | 262.17 mm | 262.17 mm |
| Cash burn (monthly) | 6.29 mm | (no burn) | 9.65 mm | 6.90 mm | 5.32 mm | 5.60 mm |
| Cash used (since last report) | 13.78 mm | n/a | 21.16 mm | 15.12 mm | 11.66 mm | 12.28 mm |
| Cash remaining | 248.39 mm | n/a | 241.01 mm | 247.05 mm | 250.52 mm | 249.89 mm |
| Runway (months of cash) | 39.5 | n/a | 25.0 | 35.8 | 47.1 | 44.6 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 61 |
| Opened positions | 12 |
| Closed positions | 6 |
| Increased positions | 29 |
| Reduced positions | 5 |
| 13F shares | Current |
|---|---|
| Total value | 415.45 bn |
| Total shares | 48.09 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Frazier Life Sciences Management | 9.76 mm | $163.26 bn |
| Frazier Life Sciences Public Fund | 8.54 mm | $145.53 mm |
| TAK Takeda Pharmaceutical | 6.72 mm | $0.00 |
| Deerfield Management | 2.69 mm | $45.07 bn |
| Flynn James E | 2.69 mm | $0.00 |
| Lightspeed Venture Partners Select IV | 1.90 mm | $38.42 mm |
| Abingworth | 1.84 mm | $30.76 bn |
| CG Carlyle Group Inc | 1.84 mm | $0.00 |
| Ra Capital Management | 1.76 mm | $29.45 bn |
| Braidwell | 1.62 mm | $27.11 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 8 May 23 | Nanette Cocero | Stock Option Common Stock | Grant | Acquire A | No | No | 14.2 | 34,000 | 482.80 k | 34,000 |
| 1 Feb 23 | Shane Maltbie | Common Stock | Grant | Acquire A | No | No | 0 | 43,333 | 0.00 | 44,232 |
| 1 Feb 23 | Shane Maltbie | Stock Option Common Stock | Grant | Acquire A | No | No | 18 | 65,000 | 1.17 mm | 65,000 |
| 1 Feb 23 | Hershberg Robert | Common Stock | Grant | Acquire A | No | No | 0 | 187,966 | 0.00 | 965,428 |
| 1 Feb 23 | Hershberg Robert | Stock Option Common Stock | Grant | Acquire A | No | No | 18 | 381,950 | 6.88 mm | 381,950 |
| 1 Feb 23 | Astrid Borkowski | Common Stock | Grant | Acquire A | No | No | 0 | 51,333 | 0.00 | 219,774 |
| 1 Feb 23 | Astrid Borkowski | Stock Option Common Stock | Grant | Acquire A | No | No | 18 | 77,000 | 1.39 mm | 77,000 |
Press releases
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
12 May 23
HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors
9 May 23
HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate
25 Apr 23
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
17 Mar 23